Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02046369 · ClinicalTrials.gov registry record · Phase 3
Lurasidone Pediatric Bipolar Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT02046369 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 350 participants.
The verdict
NCT02046369, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
Interventions
- DRUG Placebo
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02046369
The ClinicalTrials.gov registry entry for NCT02046369 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02046369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02046369 about?
NCT02046369 is a clinical study titled "Lurasidone Pediatric Bipolar Study". A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression
What is the current status of trial NCT02046369?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2014-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02046369?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT02046369?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.